Annual Report and Accounts

Hutchison China Meditech Limited
09 April 2008


                  Hutchison China MediTech Limited ('Chi-Med')

                                  (AIM: HCM)

                            Annual Report 2007 and
                       Notice of Annual General Meeting


London, Wednesday, 9 April 2008: Chi-Med today announces that its Annual Report
2007 together with the Notice of Annual General Meeting ('AGM') and the Proxy
Form have been posted to shareholders.  The documents can be accessed from the
website of Chi-Med (www.chi-med.com).

The AGM of Chi-Med will be held at Citigate Dewe Rogerson, 3 London Wall
Buildings, London, EC2M 5SY on Friday, 9 May 2008 at 2:30 p.m.


                                      Ends


Enquiries


  Chi-Med                                    Telephone: [phone]

  Christian Hogg, CEO


  Citigate Dewe Rogerson                     Telephone: [phone]

  Anthony Carlisle                           [phone]

  David Dible                                [phone]


About Chi-Med


Chi-Med is the holding company of a pharmaceutical and healthcare group focused
on Traditional Chinese Medicine ('TCM') based primarily in China and was
admitted to trading on the Alternative Investment Market of the London Stock
Exchange in May 2006. Chi-Med operates three core business segments: 1) China
healthcare - the manufacture, distribution and marketing of pharmaceuticals and
health supplements in China; 2) Drug R&D - the discovery and global development
of novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumer
products - global retailing and distribution consumer health and personal care
products derived from TCM and botanical ingredients.


Chi-Med is majority owned by Hutchison Whampoa Limited, an international company
listed on the Main Board of The Stock Exchange of Hong Kong Limited.


                      This information is provided by RNS
            The company news service from the London Stock Exchange                GGGII